Anti-cancer agent

Patent metadata

Field	Value
Publication number	US-10111892-B2
Application number	US-201013513909-A
Country	US
Kind code	B2
Filing date	Dec 20, 2010
Priority date	Dec 21, 2009
Publication date	Oct 30, 2018
Grant date	Oct 30, 2018

Abstract

The anti-cancer agent of the present invention contains at least one kind of phosphine transition metal complex selected from a group of compounds represented by the following Formulae (1a) to (1d). According to this anti-cancer agent, an anti-cancer agent is provided which has a higher anti-cancer activity and lower toxicity compared to anti-cancer agents in the related art. In Formulae (1a), (1b), (1c), and (1d), R 1 and R 2 represent a linear or branched alkyl group, and R 1 has a higher priority than R 2 as ranked according to RS notation. R 3 and R 4 represent a hydrogen atom or a linear or branched alkyl group. M represents an atom of a transition metal selected from a group consisting of gold, copper, and silver. X − represents an anion.

First claim

The invention claimed is:

1. An anti-cancer agent comprising:
at least one kind of phosphine transition metal complex selected from a group of compounds represented by Formulae (1a) to (1d),

at least one kind of phosphine transition metal complex selected from a group of compounds represented by Formulae (2a) to (2c),

and
a phosphine transition metal complex represented by Formula (3),

wherein in the Formulae, R 1 and R 2 represent a linear or branched alkyl group, a cycloalkyl group, a cycloalkyl group having a substituent, an adamantyl group, a phenyl group, or a phenyl group having a substituent that has 1 to 10 carbon atoms; R 1 and R 2 are different from each other, and R 1 has a higher priority than R 2 as ranked according to RS notation; R 3 and R 4 represent a hydrogen atom or a linear or branched alkyl group having 1 to 6 carbon atoms, and may be groups that are the same as or different from each other; R 3 and R 4 may form a saturated or unsaturated ring by binding to each other, and the saturated or unsaturated ring may have a substituent; M represents an atom of a transition metal selected from a group consisting of gold, copper, and silver; and X − represents an anion; and
wherein the mixing ratio (molar ratio) among the total amount of the compounds represented by Formulae (1a) to (1d), the total amount of the compounds represented by Formulae (2a) to (2c), and the compound represented by Formula (3) is Formulae (1a) to (1d):Formulae (2a) to (2c):Formula (3)=20 to 80:10 to 30:10 to 80.

2. An anti-cancer agent comprising:
at least one kind of phosphine transition metal complex selected from a group of compounds represented by Formulae (1a) to (1d),

at least one kind of phosphine transition metal complex selected from a group of compounds represented by Formulae (2a) to (2c),

and
a phosphine transition metal complex represented by Formula (3),

wherein in the Formulae, R 1 and R 2 represent a linear or branched alkyl group, a cycloalkyl group, a cycloalkyl group having a substituent, an adamantyl group, a phenyl group, or a phenyl group having a substituent that has 1 to 10 carbon atoms; R 1 and R 2 are different from each other, and R 1 has a higher priority than R 2 as ranked according to RS notation; R 3 and R 4 represent a hydrogen atom or a linear or branched alkyl group having 1 to 6 carbon atoms, and may be groups that are the same as or different from each other; R 3 and R 4 may form a saturated or unsaturated ring by binding to each other, and the saturated or unsaturated ring may have a substituent; M represents an atom of a transition metal selected from a group consisting of gold, copper, and silver; and X − represents an anion; and
wherein the mixing ratio (molar ratio) among the total amount of the compounds represented by Formulae (1a) to (1d), the total amount of the compounds represented by Formulae (2a) to (2c), and the compound represented by Formula (3) is Formulae (1a) to (1d):Formulae (2a) to (2c):Formula (3)=40 to 70:5 to 25:15 to 50.

Assignees

• Oohara Nobuhiko
• Nakatsui Kazuhiro
• Nippon Chemical Ind

Inventors

• Oohara Nobuhiko
• Nakatsui Kazuhiro

Classifications

• C07F9/650952

  having the nitrogen atoms in the positions 1 and 4 · CPC title

• A61K31/675 Primary

  having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate · CPC title

• C07F9/6509

  Six-membered rings · CPC title

• A61K9/0053

  Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title